A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenocarcinoma

Elena G. Chiorean, Tomislav Dragovich, John Hamm, Carlos H. Barrios, Carlos F. Gorini, Virginia K. Langmuir, Stewart Kroll, Donald T. Jung, George T. Tidmarsh, Patrick Loehrer

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objectives: A dose-escalation study of glufosfamide plus gemcitabine showed that the combination could be administered safely at full doses. The purpose of this phase II study was to evaluate the safety and efficacy of this combination in chemotherapy-naive pancreatic adenocarcinoma. Methods: Eligible patients had metastatic and/or locally advanced pancreatic adenocarcinoma, Karnofsky performance status ≥70, creatinine clearance (CrCL) ≥60 mL/min, and acceptable organ function. Patients received glufosfamide 4500 mg/m intravenous on day 1 and gemcitabine 1000 mg/m intravenous on Days 1, 8, and 15 of every 28-day cycle. The primary end point was response rate. Results: Twenty-nine patients were enrolled; 14 male, median age 58 years. Twenty-three (79%) patients had distant metastases. Median cycles on treatment was 4 (range: 1-18+). Of 28, 5 (18%; 95% CI: 6%-37%) patients had a confirmed partial response (median duration: 8.4 months) and 1 had an unconfirmed partial response. Eleven patients (39%) had stable disease. Median progression-free survival was 3.7 months, median overall survival was 6 months, and 1-year survival was 32%. Grade 3/4 neutropenia occurred in 23 (79%) patients and grade 3/4 thrombocytopenia in 10 (34%) patients. The CrCL fell below 60 mL/min in 10 of 27 (37%) patients. Renal failure occurred in 4 patients. Decrease in CrCL was correlated with glufosfamide and isophosphoramide mustard pharmacokinetic area under the curve. Conclusions: The combination of glufosfamide plus gemcitabine is active in pancreatic cancer; however, hematologic and renal toxicity were pronounced. Alternative dosing of glufosfamide plus gemcitabine should be explored.

Original languageEnglish
Pages (from-to)111-116
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume33
Issue number2
DOIs
StatePublished - Apr 2010

Fingerprint

gemcitabine
Adenocarcinoma
Drug Therapy
Creatinine
beta-D-glucosylisophosphoramide mustard
Karnofsky Performance Status
Survival

Keywords

  • Antineoplastic combined chemotherapy protocols
  • Deoxycytidine
  • Pancreatic neoplasms
  • Phosphoramide mustards
  • Survival analysis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenocarcinoma. / Chiorean, Elena G.; Dragovich, Tomislav; Hamm, John; Barrios, Carlos H.; Gorini, Carlos F.; Langmuir, Virginia K.; Kroll, Stewart; Jung, Donald T.; Tidmarsh, George T.; Loehrer, Patrick.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 33, No. 2, 04.2010, p. 111-116.

Research output: Contribution to journalArticle

Chiorean, Elena G. ; Dragovich, Tomislav ; Hamm, John ; Barrios, Carlos H. ; Gorini, Carlos F. ; Langmuir, Virginia K. ; Kroll, Stewart ; Jung, Donald T. ; Tidmarsh, George T. ; Loehrer, Patrick. / A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenocarcinoma. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2010 ; Vol. 33, No. 2. pp. 111-116.
@article{91d778b3fff548b6b38be116c612a1d2,
title = "A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenocarcinoma",
abstract = "Objectives: A dose-escalation study of glufosfamide plus gemcitabine showed that the combination could be administered safely at full doses. The purpose of this phase II study was to evaluate the safety and efficacy of this combination in chemotherapy-naive pancreatic adenocarcinoma. Methods: Eligible patients had metastatic and/or locally advanced pancreatic adenocarcinoma, Karnofsky performance status ≥70, creatinine clearance (CrCL) ≥60 mL/min, and acceptable organ function. Patients received glufosfamide 4500 mg/m intravenous on day 1 and gemcitabine 1000 mg/m intravenous on Days 1, 8, and 15 of every 28-day cycle. The primary end point was response rate. Results: Twenty-nine patients were enrolled; 14 male, median age 58 years. Twenty-three (79{\%}) patients had distant metastases. Median cycles on treatment was 4 (range: 1-18+). Of 28, 5 (18{\%}; 95{\%} CI: 6{\%}-37{\%}) patients had a confirmed partial response (median duration: 8.4 months) and 1 had an unconfirmed partial response. Eleven patients (39{\%}) had stable disease. Median progression-free survival was 3.7 months, median overall survival was 6 months, and 1-year survival was 32{\%}. Grade 3/4 neutropenia occurred in 23 (79{\%}) patients and grade 3/4 thrombocytopenia in 10 (34{\%}) patients. The CrCL fell below 60 mL/min in 10 of 27 (37{\%}) patients. Renal failure occurred in 4 patients. Decrease in CrCL was correlated with glufosfamide and isophosphoramide mustard pharmacokinetic area under the curve. Conclusions: The combination of glufosfamide plus gemcitabine is active in pancreatic cancer; however, hematologic and renal toxicity were pronounced. Alternative dosing of glufosfamide plus gemcitabine should be explored.",
keywords = "Antineoplastic combined chemotherapy protocols, Deoxycytidine, Pancreatic neoplasms, Phosphoramide mustards, Survival analysis",
author = "Chiorean, {Elena G.} and Tomislav Dragovich and John Hamm and Barrios, {Carlos H.} and Gorini, {Carlos F.} and Langmuir, {Virginia K.} and Stewart Kroll and Jung, {Donald T.} and Tidmarsh, {George T.} and Patrick Loehrer",
year = "2010",
month = "4",
doi = "10.1097/COC.0b013e3181979204",
language = "English",
volume = "33",
pages = "111--116",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenocarcinoma

AU - Chiorean, Elena G.

AU - Dragovich, Tomislav

AU - Hamm, John

AU - Barrios, Carlos H.

AU - Gorini, Carlos F.

AU - Langmuir, Virginia K.

AU - Kroll, Stewart

AU - Jung, Donald T.

AU - Tidmarsh, George T.

AU - Loehrer, Patrick

PY - 2010/4

Y1 - 2010/4

N2 - Objectives: A dose-escalation study of glufosfamide plus gemcitabine showed that the combination could be administered safely at full doses. The purpose of this phase II study was to evaluate the safety and efficacy of this combination in chemotherapy-naive pancreatic adenocarcinoma. Methods: Eligible patients had metastatic and/or locally advanced pancreatic adenocarcinoma, Karnofsky performance status ≥70, creatinine clearance (CrCL) ≥60 mL/min, and acceptable organ function. Patients received glufosfamide 4500 mg/m intravenous on day 1 and gemcitabine 1000 mg/m intravenous on Days 1, 8, and 15 of every 28-day cycle. The primary end point was response rate. Results: Twenty-nine patients were enrolled; 14 male, median age 58 years. Twenty-three (79%) patients had distant metastases. Median cycles on treatment was 4 (range: 1-18+). Of 28, 5 (18%; 95% CI: 6%-37%) patients had a confirmed partial response (median duration: 8.4 months) and 1 had an unconfirmed partial response. Eleven patients (39%) had stable disease. Median progression-free survival was 3.7 months, median overall survival was 6 months, and 1-year survival was 32%. Grade 3/4 neutropenia occurred in 23 (79%) patients and grade 3/4 thrombocytopenia in 10 (34%) patients. The CrCL fell below 60 mL/min in 10 of 27 (37%) patients. Renal failure occurred in 4 patients. Decrease in CrCL was correlated with glufosfamide and isophosphoramide mustard pharmacokinetic area under the curve. Conclusions: The combination of glufosfamide plus gemcitabine is active in pancreatic cancer; however, hematologic and renal toxicity were pronounced. Alternative dosing of glufosfamide plus gemcitabine should be explored.

AB - Objectives: A dose-escalation study of glufosfamide plus gemcitabine showed that the combination could be administered safely at full doses. The purpose of this phase II study was to evaluate the safety and efficacy of this combination in chemotherapy-naive pancreatic adenocarcinoma. Methods: Eligible patients had metastatic and/or locally advanced pancreatic adenocarcinoma, Karnofsky performance status ≥70, creatinine clearance (CrCL) ≥60 mL/min, and acceptable organ function. Patients received glufosfamide 4500 mg/m intravenous on day 1 and gemcitabine 1000 mg/m intravenous on Days 1, 8, and 15 of every 28-day cycle. The primary end point was response rate. Results: Twenty-nine patients were enrolled; 14 male, median age 58 years. Twenty-three (79%) patients had distant metastases. Median cycles on treatment was 4 (range: 1-18+). Of 28, 5 (18%; 95% CI: 6%-37%) patients had a confirmed partial response (median duration: 8.4 months) and 1 had an unconfirmed partial response. Eleven patients (39%) had stable disease. Median progression-free survival was 3.7 months, median overall survival was 6 months, and 1-year survival was 32%. Grade 3/4 neutropenia occurred in 23 (79%) patients and grade 3/4 thrombocytopenia in 10 (34%) patients. The CrCL fell below 60 mL/min in 10 of 27 (37%) patients. Renal failure occurred in 4 patients. Decrease in CrCL was correlated with glufosfamide and isophosphoramide mustard pharmacokinetic area under the curve. Conclusions: The combination of glufosfamide plus gemcitabine is active in pancreatic cancer; however, hematologic and renal toxicity were pronounced. Alternative dosing of glufosfamide plus gemcitabine should be explored.

KW - Antineoplastic combined chemotherapy protocols

KW - Deoxycytidine

KW - Pancreatic neoplasms

KW - Phosphoramide mustards

KW - Survival analysis

UR - http://www.scopus.com/inward/record.url?scp=77951044356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951044356&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e3181979204

DO - 10.1097/COC.0b013e3181979204

M3 - Article

C2 - 19687729

AN - SCOPUS:77951044356

VL - 33

SP - 111

EP - 116

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 2

ER -